Free Trial

PureTech Health (LON:PRTC) Stock Price Down 12.4% - Should You Sell?

PureTech Health logo with Medical background

Shares of PureTech Health plc (LON:PRTC - Get Free Report) were down 12.4% during mid-day trading on Thursday . The company traded as low as GBX 100.40 ($1.32) and last traded at GBX 103 ($1.36). Approximately 3,018,245 shares were traded during trading, an increase of 192% from the average daily volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.55).

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group reissued a "buy" rating and set a GBX 455 ($6.00) target price on shares of PureTech Health in a research note on Monday, December 16th.

Read Our Latest Stock Analysis on PureTech Health

PureTech Health Stock Performance

The business has a fifty day simple moving average of GBX 134.79 and a two-hundred day simple moving average of GBX 147.92. The company has a market cap of £373.67 million, a PE ratio of -5.10 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Recommended Stories

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Big Week Reveals a Rare Growth Story in a Shaky Market
Buy the Fear: 3 Down Stocks That Could 10x Your Profits
Congress Bought THESE Stocks as Tariffs Tanked the Market

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines